Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini GC, Bonmassar L, Alvino E, Caporali S, Lacal PM, Narducci MG, Molineris I, De Galitiis F, Negrini M, Russo G, D'Atri S. Levati L, et al. Among authors: mastroeni s. Cancers (Basel). 2022 Jul 29;14(15):3706. doi: 10.3390/cancers14153706. Cancers (Basel). 2022. PMID: 35954369 Free PMC article.
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.
Caporali S, Alvino E, Lacal PM, Ruffini F, Levati L, Bonmassar L, Scoppola A, Marchetti P, Mastroeni S, Antonini Cappellini GC, D'Atri S. Caporali S, et al. Among authors: mastroeni s. Oncotarget. 2017 Dec 9;8(69):113472-113493. doi: 10.18632/oncotarget.23052. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371923 Free PMC article.
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, Carè A, Pfeffer U, D'Atri S. Caporali S, et al. Among authors: mastroeni s. J Exp Clin Cancer Res. 2019 Jun 21;38(1):272. doi: 10.1186/s13046-019-1238-4. J Exp Clin Cancer Res. 2019. PMID: 31227006 Free PMC article.
Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR, Verkhovskaia S, Mastroeni S, Carbone ML, Abeni D, Di Rocco CZ, Samà N, Zappalà AR, Marchetti P, De Galitiis F, Failla CM, Fortes C. Di Pietro FR, et al. Among authors: mastroeni s. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e18-e24. doi: 10.1016/j.clon.2021.09.006. Epub 2021 Sep 23. Clin Oncol (R Coll Radiol). 2022. PMID: 34563446
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S, Di Pietro FR, Mastroeni S, Carbone ML, Abeni D, Morese R, Morelli FM, D'Atri S, Marchetti P, De Galitiis F, Failla CM, Fortes C. Verkhovskaia S, et al. Among authors: mastroeni s. J Cancer Res Clin Oncol. 2022 Sep;148(9):2529-2538. doi: 10.1007/s00432-021-03811-3. Epub 2021 Sep 30. J Cancer Res Clin Oncol. 2022. PMID: 34595541
Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma.
Tosi A, Nardinocchi L, Carbone ML, Capriotti L, Pagani E, Mastroeni S, Fortes C, Scopelliti F, Cattani C, Passarelli F, Rosato A, D'Atri S, Failla CM, Cavani A. Tosi A, et al. Among authors: mastroeni s. Biomedicines. 2021 Dec 16;9(12):1930. doi: 10.3390/biomedicines9121930. Biomedicines. 2021. PMID: 34944746 Free PMC article.
Early inflammatory biomarkers and melanoma survival.
Fortes C, Mastroeni S, Zappalà AR, Passarelli F, Ricci F, Abeni D, Michelozzi P. Fortes C, et al. Among authors: mastroeni s. Int J Dermatol. 2023 Jun;62(6):752-758. doi: 10.1111/ijd.16629. Epub 2023 Mar 5. Int J Dermatol. 2023. PMID: 36872079
100 results